Recently Viewed
empty-cart

There are no Recent Items

Close
Login/Register

Close
Single User License Price USD 2000
Single User License Price INR 134900
Corporate User License Price USD 6000
Corporate User License Price INR 404700
Site License Price USD 4000
Site License Price INR 269800
Request a Quote

Report Title

Allergic Conjunctivitis-Pipeline Review, H1 2017

Quote Request for License Type
License Type Price  
Single User License USD 2000
Site License USD 4000
Enterprise Wide License USD 6000
"Thanks for submitting the form. Our marketing team will connect back to you for the budget constraint."
Close
REQUEST A CUSTOMIZED RESEARCH

Report Title

Allergic Conjunctivitis-Pipeline Review, H1 2017


Quote Request for License Type
License Type Price  
Single User License USD 2000
"Thanks for letting us know your requirement. Our research team will connect back to you for the bespoke requirement."
Close
REQUEST FOR SAMPLE REPORT

Report Title

Allergic Conjunctivitis-Pipeline Review, H1 2017

"Thanks for submitting the form. The concerned team will send the sample report in the next 12 hours."
"Thank you for downloading the sample report."
Close

Allergic Conjunctivitis-Pipeline Review, H1 2017



Executive Summary

Allergic Conjunctivitis-Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Allergic Conjunctivitis-Pipeline Review, H1 2017, provides an overview of the Allergic Conjunctivitis (Ophthalmology) pipeline landscape.

Allergic conjunctivitis occurs when the clear layer of tissue lining the eyelids and covering the white of the eye (conjunctiva) become swollen or inflamed due to a reaction to pollen, dander, mold, or other allergy-causing substances. Symptoms include intense itching, puffy eyelids, widened (dilated) vessels in the clear tissue covering the white of the eye and stringy eye discharge. Treatment includes antihistamine or anti-inflammatory medication.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Allergic Conjunctivitis-Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Allergic Conjunctivitis (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Allergic Conjunctivitis (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Allergic Conjunctivitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 3, 2, 10 and 1 respectively.

Allergic Conjunctivitis (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Allergic Conjunctivitis (Ophthalmology).

The pipeline guide reviews pipeline therapeutics for Allergic Conjunctivitis (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Allergic Conjunctivitis (Ophthalmology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Allergic Conjunctivitis (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Allergic Conjunctivitis (Ophthalmology)

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Allergic Conjunctivitis (Ophthalmology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Allergic Conjunctivitis (Ophthalmology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Allergic Conjunctivitis-Overview

Allergic Conjunctivitis-Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Allergic Conjunctivitis-Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Allergic Conjunctivitis-Companies Involved in Therapeutics Development

Accolade Pharmaceuticals LLC

Aldeyra Therapeutics Inc

AlleCures Inc

Allergan Plc

Clevexel Pharma SAS

Griffin Discoveries BV

NicOx SA

Ocular Therapeutix Inc

Ohr Pharmaceutical Inc

Portola Pharmaceuticals Inc

Re-Pharm Ltd

Realm Therapeutics Plc

Sylentis SAU

Xencor Inc

Allergic Conjunctivitis-Drug Profiles

ADX-102-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AGN-229666-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Allergen for Allergic Conjunctivitis and Allergic Rhinitis-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

cetirizine hydrochloride-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CPC-888-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CVXL-0074-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dexamethasone acetate SR-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drugs for Allergic Conjunctivitis-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GD-134-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GD-136-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PR-013-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PRT-2761-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RP-0217-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize Histamine H1 and H4 Receptor for Ophthalmology and Asthma-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ST-266-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SYL-116011-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

XmAb-7195-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Zafi-2-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

zafirlukast-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Allergic Conjunctivitis-Dormant Projects

Allergic Conjunctivitis-Discontinued Products

Allergic Conjunctivitis-Product Development Milestones

Featured News & Press Releases

Apr 18, 2017: Aldeyra Therapeutics Announces Last Patient Dosed in Allergic Conjunctivitis Phase 2b Clinical Trial

Apr 11, 2017: Nicox announces PDUFA date for ZERVIATE NDA

Mar 09, 2017: Nicox resubmits AC-170 (ZERVIATE) NDA to the US FDA

Feb 07, 2017: Aldeyra Therapeutics Announces First Patient Enrolled in Allergic Conjunctivitis Phase 2b Clinical Trial

Jan 05, 2017: Realm Therapeutics to provide update on PR013 at the 2017 Dermatology Summit and Biotech Showcase

Dec 05, 2016: Noveome Initiates Phase 2 Clinical Trial of ST266 for the Treatment of Allergic Conjunctivitis

Nov 16, 2016: PuriCore provides update on key development program PR013

Nov 09, 2016: Nicox Provides Update on Latanoprostene bunod and AC-170

Nov 07, 2016: Aldeyra Therapeutics Announces Presentation of Phase 2 Allergic Conjunctivitis Results at the 2016 American College of Allergy, Asthma and Immunology Annual Scientific Meeting

Oct 10, 2016: Nicox Receives Complete Response Letter from the FDA Related to GMP on NDA for AC-170

Sep 26, 2016: Aldeyra Therapeutics Provides Update on Late-Stage Clinical Trials at 2016 Research and Development Day

Jun 21, 2016: U.S. FDA grants Priority Review for Nicox AC-170 New Drug Application

Jun 06, 2016: Ocular Therapeutix Announces Topline Results of Second Phase 3 Clinical Trial of DEXTENZA for the Treatment of Allergic Conjunctivitis

Apr 19, 2016: Nicox submits New Drug Application for AC-170 to U.S. FDA

Feb 29, 2016: Aldeyra Therapeutics Reports Positive Results From Phase IIa Clinical Trial in Subjects With Allergic Conjunctivitis

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

To know more information on Purchase by Section, please send a mail to sales@kenresearch.com

List of Figures

Number of Products under Development for Allergic Conjunctivitis, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Mechanism of Actions, H1 2017

Number of Products by Stage and Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Top 10 Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

List of Tables

Number of Products under Development for Allergic Conjunctivitis, H1 2017

Number of Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Allergic Conjunctivitis-Pipeline by Accolade Pharmaceuticals LLC, H1 2017

Allergic Conjunctivitis-Pipeline by Aldeyra Therapeutics Inc, H1 2017

Allergic Conjunctivitis-Pipeline by AlleCures Inc, H1 2017

Allergic Conjunctivitis-Pipeline by Allergan Plc, H1 2017

Allergic Conjunctivitis-Pipeline by Clevexel Pharma SAS, H1 2017

Allergic Conjunctivitis-Pipeline by Griffin Discoveries BV, H1 2017

Allergic Conjunctivitis-Pipeline by NicOx SA, H1 2017

Allergic Conjunctivitis-Pipeline by Ocular Therapeutix Inc, H1 2017

Allergic Conjunctivitis-Pipeline by Ohr Pharmaceutical Inc, H1 2017

Allergic Conjunctivitis-Pipeline by Portola Pharmaceuticals Inc, H1 2017

Allergic Conjunctivitis-Pipeline by Re-Pharm Ltd, H1 2017

Allergic Conjunctivitis-Pipeline by Realm Therapeutics Plc, H1 2017

Allergic Conjunctivitis-Pipeline by Sylentis SAU, H1 2017

Allergic Conjunctivitis-Pipeline by Xencor Inc, H1 2017

Allergic Conjunctivitis-Dormant Projects, H1 2017

Allergic Conjunctivitis-Dormant Projects, H1 2017 (Contd..1), H1 2017

Allergic Conjunctivitis-Discontinued Products, H1 2017

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Accolade Pharmaceuticals LLC, Aldeyra Therapeutics Inc, AlleCures Inc, Allergan Plc, Clevexel Pharma SAS, Griffin Discoveries BV, NicOx SA, Ocular Therapeutix Inc, Ohr Pharmaceutical Inc, Portola Pharmaceuticals Inc, Re-Pharm Ltd, Realm Therapeutics Plc, Sylentis SAU, Xencor Inc

Allergic Conjunctivitis Therapeutic Products under Development, Key Players in Allergic Conjunctivitis Therapeutics, Allergic Conjunctivitis Pipeline Overview, Allergic Conjunctivitis Pipeline, Allergic Conjunctivitis Pipeline Assessment


Related Products in vertical
red-whiteline

RECENT VIEWED REPORTS



Sign up for newsletter

Close
Apply For Job

  • Applicant Name
  • Job Function
  • Total Experience
  • Skills
  • Email ID
  • Notice Period
  • Current CTC & Expected CTC
  • Phone Number
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Your resume has been successfully received. HR will connect you within 14 days in case your resume gets shortlisted."
Close
Download Company Brochure

  • Name
  • Email
  • Company Name
  • Select Country*
  • Phone Number
  • Validation
  •   info-icon

    If validation code does not match, please refresh the page.

Close
Engage With Us

  • Name
  • Designation
  • Email
  • Phone No.
  • Company Name
  • Company URL
  • Select Country*
  • Requirements/ Comments
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Thanks for submitting the form. The concerned team will respond to your query in the next 8-12 hours"
Close

Compare

Expand